Inventia Life Science, Australia-based biotech company, has announced a new distribution agreement with Mumbai-based Biotron Healthcare, for Inventia Life Science’s flagship RASTRUM platform to enter the Indian market.

The RASTRUM platform, a game changer in the field of advanced cell model creation, helps researchers accelerate the quest to investigate and cure debilitating diseases such as cancer, neurodegenerative and fibrotic diseases.

With applications in biomedical research including drug discovery, disease modeling and fundamental biological research, the RASTRUM platform is making physiologically relevant disease models a reality.

RASTRUM is designed specifically for cell biology and is a world-first technology. The platform is highly automated which creates complex, miniaturised 3D cell cultures quickly by printing hydrogels and cells in a highly controlled way. 

Venkatesh Voleti, Director – Sales at Biotron Healthcare said, “We can address users especially in High Throughput Screening in Pharma, CRO and related domains by taking away their challenges of spending resources in standardisation. The users can thus focus on their downstream applications. Many of these users are keen and already planning to shift their assays from 2D to 3D Cell culture models. We look forward to bringing this unique and successful platform from Inventia Life Sciences to this growing 3D Cell Culture community in India in the field of Cell Biology."